Clinical Trials Browser

Recruiting × Carcinoma, Non-Small-Cell Lung × Radiation Dose Hypofractionation × Clear all

NCT06379087 2025-07-10

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

Phase 2 Recruiting

Carcinoma, Non-Small-Cell Lung